John Stephens, MD
Ophthalmology · Cape Coral, FLNPI 1134549967
Payments from drug & device makers
Across 460 payments — averaging $492.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$149K
- Glaukos Corporation$34K
- Bausch & Lomb Americas Inc.$17K
- Rxsight Inc$12K
- Alcon$8K
- Lensar, Inc.$4K
- plus $3K from 23 others
Across 1 payment — averaging $10,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lensar, Inc.$11K
What the payments were for
- Consulting fees$61,93927%
- Speaking & faculty fees$124,65155%
- Travel & lodging$23,99411%
- Food & beverage$15,8927%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 239 | $149,053 |
| Glaukos Corporation | 58 | $34,054 |
| Bausch & Lomb Americas Inc. | 45 | $16,658 |
| Rxsight Inc | 10 | $12,180 |
| Alcon | 32 | $8,207 |
| Lensar, Inc. | 10 | $3,711 |
| Biotissue Holdings Inc. | 6 | $437 |
| Dompe US, Inc. | 10 | $375 |
| Carl Zeiss Meditec Cataract Technology Inc. | 9 | $316 |
| Aerie Pharmaceuticals, Inc. | 7 | $255 |
| Dutch Ophthalmic, USA | 3 | $195 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $187 |
| Carl Zeiss Meditec USA, Inc. | 3 | $165 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $115 |
| Bausch Health US, LLC | 1 | $102 |
| Tarsus Pharmaceuticals, Inc. | 1 | $88 |
| Ocular Therapeutix, Inc. | 4 | $73 |
| Sun Pharmaceutical Industries Inc. | 3 | $56 |
| Sight Sciences, Inc. | 2 | $34 |
| Topcon Healthcare, Inc. | 1 | $30 |
| Carl Zeiss Meditec, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Shire North American Group Inc | 1 | $25 |
| Alimera Sciences, Inc. | 1 | $18 |
| NEW World Medical,inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$145,715
- Travoprost Intraocular Implant - iDose$15,789
- STELLARIS ELITE$15,440
- enVista MX60 IOL$13,831
- Trulign IOL$13,831
- Crystalens Accommodating IOL (AT-52AO)$13,831
- iDose$8,838
- RXSIGHT CONTACT LENS$7,161
- RXSIGHT INJECTOR CARTRIDGE$7,161
- RXSIGHT INJECTOR HANDPIECE$7,161
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$7,161
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$7,161
- Clareon$5,273
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$4,960
- LENSAR LASER SYSTEM$3,579
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$2,750
- AcrySof IQ PanOptix UV IOL$1,710
- AcrySof IQ VIVITY$1,710
- enVista Aspire IOL$1,609
- TENEO$1,609
How this compares
$226,494 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $340,437 |
| RestasisCyclosporine | 59 | $71,396 |
| LumiganBimatoprost | 72 | $42,098 |
| VyzultaLatanoprostene Bunod | 55 | $33,205 |
| RhopressaNetarsudil Mesylate | 41 | $26,445 |
| Prednisolone Acetate | 288 | $11,784 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $9,982 |
| Travoprost | 34 | $8,641 |
| Brimonidine Tartrate | 190 | $7,790 |
| Latanoprost | 586 | $7,089 |
| Alphagan PBrimonidine Tartrate | 16 | $6,045 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,192 |
| Timolol Maleate | 404 | $4,505 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 237 | $4,447 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 20 | $3,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $375 | $340,43712 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $149,053 | $129,520161 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $16,658 | $33,20555 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $255 | $26,44541 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $187 | $2,59516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Cape Coral
- Farrell TysonCape Coral$885K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.